Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Oxaliplatin in Advanced Ovarian Cancer
NCT00075543Phase 2Unknown
- Sponsor
- GERCOR
- Start
- Jul 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and oxaliplatin in ovarian epithelial cancer, sponsored by GERCOR. Primary endpoints: Maximum Tolerated Dose and Toxicity. Status: unknown.
02
Drugs
docetaxeloxaliplatin
03
Conditions
ovarian epithelial cancer
Beyond the preview
Go deeper on NCT00075543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075543.